Circulating Levels of Secretory Type II Phospholipase A2 Predict Coronary Events in Patients with Coronary Artery Disease

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Circulation

• Publication date

  1999-09-21

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Modulation of immunity by the secreted phospholipase A2 family

  2023cites this paper
• Association between serum secretory phospholipase A2 and risk of ischaemic stroke

  2021cites this paper
• Expression of Protein Markers of Adipogenesis in Endometriotic Lesions

  2020cites this paper
• Serum Bilirubin and Coronary Artery Disease: Intricate Relationship, Pathophysiology, and Recent Evidence.

  2019cites this paper
• Lipoquality control by phospholipase A2 enzymes

  2017cites this paper
• Immune-mediated mechanisms of atherosclerosis and implications for the clinic

  2016cites this paper
• Multivalent nanoparticle networks enable point-of-care detection of human phospholipase-A2 in serum.

  2015cites this paper
• Macrophages in atherosclerosis: a dynamic balance

  2013cites this paper
• Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010 – present)

  2013cites this paper
• Traditional and Novel Risk Factors in Atherothrombosis

  2012cites this paper
• Acute Phase Reactants as Novel Predictors of Cardiovascular Disease

  2012influential citation
• Telmisartan and N-acetylcysteine Suppress Group V Secretory Phospholipase A2 Expression in TNF&agr;-stimulated Human Endothelial Cells and Reduce Associated Atherogenicity

  2012cites this paper
• In search for novel biomarkers of acute coronary syndrome.

  2012cites this paper
• Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics

  2011cites this paper
• Integrated Lipidomics in the Secreted Phospholipase A2 Biology

  2011cites this paper
• Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.

  2011cites this paper
• Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link.

  2010cites this paper
• Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease

  2009cites this paper
• Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease.

  2009cites this paper
• Secretory phospholipase A2 increases SR-BI-mediated selective uptake from HDL but not biliary cholesterol secretions⃞s⃞ The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of two figures. Published, JLR Papers in Press, November 25, 2007.

  2008cites this paper
• Biology of Secretory Phospholipase A2

  2008cites this paper
• Reduction in Myocardial Ischemia/Reperfusion Injury in Group X Secretory Phospholipase A2–Deficient Mice

  2008cites this paper
• Current and emerging paradigms in the therapeutic management of atherosclerosis

  2008cites this paper
• Antifibrotic Activity of an Inhibitor of Group IIA Secretory Phospholipase A2 in Young Spontaneously Hypertensive Rats

  2006cites this paper
• Spontaneously Hypertensive Rats in Young 2 IIA Secretory Phospholipase A Antifibrotic Activity of an Inhibitor of Group

  2006cites this paper
• Inflammatory biomarkers in acute coronary syndromes: part III: biomarkers of oxidative stress and angiogenic growth factors.

  2006cites this paper
• Prevention challenges: the era of atherosclerosis regression.

  2006cites this paper
• Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study

  2005cites this paper
• Platelet reactivity, polymorphisms and premature myocardial infarction

  2005cites this paper
• Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation: Part II

  2003cites this paper
• Circulating lipoproteins as proinflammatory and anti-inflammatory particles in atherogenesis

  2003cites this paper
• Mapping the heparin binding domain of human hepatic lipase

  2002cites this paper
• Human Secretory Phospholipase A2 Mediates Decreased Plasma Levels of HDL Cholesterol and ApoA-I in Response to Inflammation in Human ApoA-I Transgenic Mice

  2002cites this paper
• Anticoagulant and Membrane-degrading Effects of Secretory (Non-pancreatic) Phospholipase A2 Are Inhibited in Plasma

  2002cites this paper
• Secretory Phospholipase A2 Elicits Proinflammatory Changes and Upregulates the Surface Expression of Fas Ligand in Monocytic Cells: Potential Relevance for Atherogenesis

  2002cites this paper
• Effects of inflammation on high-density lipoproteins.

  2002cites this paper
• Antioxidant vitamins and lipid peroxidation in patients with rheumatoid arthritis: association with inflammatory markers.

  2002cites this paper